Xenon Pharmaceuticals: Polar Capital reports 5.19%
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Xenon Pharmaceuticals Inc. (XENE) was the subject of a Schedule 13G reporting that Polar Capital Holdings Plc and Polar Capital LLP each beneficially owned 5,022,084 common shares, or 5.19% of the class, as of September 30, 2026. Each reported sole voting and dispositive power over 5,022,084 shares and no shared power. The reported percentage is based on 96,840,432 shares outstanding, which Xenon reported in its Form 10-Q on August 6, 2026.
Key Figures
Key Terms
beneficially owned financial
Sole Voting Power financial
Sole Dispositive Power financial
Rule 13d-1(k) regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.